Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crispr Therapeutics Ag (NQ: CRSP )

50.76 +4.37 (+9.42%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Crispr Therapeutics Ag

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
29 30 Next >
Google’s Bard AI Says These 3 Stocks Will Rise 1,000%
Google's Bard has been among the best stock pickers, and thinks these three stocks have quadruple-digit upside potential. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
2 Beaten-Down Growth Stocks That Could Rocket 42% to 67% Higher, According to Wall Street
Investment bank analysts are pounding the table on these stocks, but are they right for your portfolio? 
Via The Motley Fool
Could Investing $10,000 In CRISPR Therapeutics Stock Make You a Millionaire?
The stock is trading below its peak, reached a couple of years ago. 
Via The Motley Fool
3 Monster Stocks in the Making
These stocks could grow much larger over the next few years. 
Via The Motley Fool
Why CRISPR Therapeutics Stock Is Jumping Again Today
The stock continues to enjoy momentum from a key regulatory approval. 
Via The Motley Fool
Ross Stores Reports Strong Earnings, Joins Buckle, Twist Bioscience And Other Big Stocks Moving Higher On Friday
U.S. stocks traded mostly lower, with the Dow Jones falling over 20 points on Friday. 
Via Benzinga
Topics Stocks
Exposures US Equities
CRISPR Therapeutics Stock Earns 88 RS Rating On U.K. Regulator News
CRISPR Therapeutics sees its Relative Strength Rating enter the 80-plus level. 
Via Investor's Business Daily
3 Long-Term Growth Stocks Analysts Are Bullish On
Here are three long-term growth stocks for your consideration if you’re looking to take a long position in a new name or two. 
Via InvestorPlace
3 Cathie Wood You’ll Regret Not Buying Soon: November 2023
Cathie Wood thinks we're out of the woods economically, and these stock picks in her portfolio stand to gain the most in coming months. 
Via InvestorPlace
Why Is NIO Stock Down 5% Today?
Nio stock is falling on Thursday as investors react to negative news following the summit between Presidents Xi Jinping and Joe Biden. 
Via InvestorPlace
Crispr Surges After Winning The First-Ever Approval For A CRISPR-Based Gene-Editing Drug
The drug will sell under the brand name Casgevy in the UK for two blood diseases. 
Via Investor's Business Daily
What's Going On With Crispr Therapeutics Stock Thursday?
CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher Thursday after the company announced regulatory authorization of the first CRISPR/Cas9 gene- 
Via Benzinga
Citi Is Souring on Plug Power (PLUG) Stock
Plug Power stock is falling on Thursday after the EV charging company's shares were hit with a downgrade and lowered price target from Citi. 
Via InvestorPlace
CRISPR Therapeutics (CRSP) Stock Jumps as U.K. Authorizes Gene Therapy
CRSP stock is up on U.K. authorization for its gene therapy treatment for sickle cell anemia. CRISPR hopes for FDA authorization next spring. 
Via InvestorPlace
Exposures Product Safety
UK Approves First Crispr Gene Edited Therapy For Sickle Cell Disease, Beta Thalassemia
The U.K. 
Via Benzinga
Why Palo Alto Networks Shares Are Trading Lower By Around 5%; Here Are 20 Stocks Moving Premarket
Shares of Palo Alto Networks, Inc. (NASDAQ: PANW) fell in pre-market trading after reporting first-quarter results. 
Via Benzinga
Can CRISPR Therapeutics Stock Double in 5 Years? Here's What It Would Take.
A few things put together could push the stock higher. 
Via The Motley Fool
Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Invest in the Future With These 7 Forever Stocks
Forever stocks are usually those predicting future trends. Finding them today means pinning down strong financials and prospects without FOMO. 
Via InvestorPlace
3 Biotech Stocks With Key Catalysts Coming in December
Some of the most exciting opportunities can be found in biotech stocks, especially if there's a powerful catalyst just around the corner. 
Via InvestorPlace
2 Stocks to Buy Hand Over Fist as the S&P 500 Rockets Higher
These stocks look reasonably priced today considering their long-term prospects. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
What's Going On With CRISPR Therapeutics Stock?
CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher Monday after Morgan Stanley maintained the company with an Underweight rating and lowered the price target. What To Know: 
Via Benzinga
3 Biotech Stocks That Are Poised to Have Breakthroughs in 2024
Investors should consider these "Goldilocks" biotech stocks to buy as they are poised to get significant boosts next year. 
Via InvestorPlace
1 No-Brainer Stock to Buy and Hold for 10 Years
This company has been in the news for much of the year. 
Via The Motley Fool
3 Growth Stocks to Buy Right Now Without Any Hesitation
Investors shouldn't have to deliberate for too long about these great stocks. 
Via The Motley Fool
Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review
The major indexes ended long win streaks. Datadog led earnings winners. 
Via Investor's Business Daily
3 Biotech Stocks That Are Betting on the Future of Gene Editing
These three companies have gene editing therapies in late-stage clinical trials, making them promising biotech stocks to buy right now. 
Via InvestorPlace
This Program for a Common Problem May Be Vertex Pharmaceuticals' Ticket to a New Wave of Billion-Dollar Revenues
Vertex shares look cheap today considering all the company has to offer. 
Via The Motley Fool
3 Biotech Stocks With the Strongest Clinical Pipelines
Many industry heavyweights are on the hunt for fresh new ideas -- great news for biotech stocks to buy with strong pipelines. 
Via InvestorPlace
CRISPR Therapeutics Stock Earns IBD Stock Rating Upgrade
On Wednesday, CRISPR Therapeutics stock had its Relative Strength (RS) Rating upgraded to 85, up from 68 a day earlier. 
Via Investor's Business Daily
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
29 30 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.